Myconostica Overview
- Year Founded
-
2006
- Status
-
Acquired/Merged
- Employees
-
13
- Latest Deal Type
-
M&A
- Investors
-
1
Myconostica General Information
Description
Developer of molecular diagnostic fungal testing products designed to aid rapid and accurate diagnosis of life-threatening invasive fungal infections. The company offers molecular tests to identify infected patients, thereby helping clinicians to prescribe appropriate drug therapy and increase the chances of survival of those patients.
Contact Information
Website
www.myconostica.co.ukCorporate Office
- Microgen Bioproducts 1 Admiralty Way
- Camberley GU15 3DT
- England, United Kingdom
Corporate Office
- Microgen Bioproducts 1 Admiralty Way
- Camberley GU15 3DT
- England, United Kingdom
Myconostica Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 23-May-2011 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series D) | 19-Jul-2010 | Completed | Generating Revenue | |||
| 4. Early Stage VC | 09-Apr-2008 | Completed | Product Development | |||
| 3. Early Stage VC | 30-Jul-2007 | Completed | Product Development | |||
| 2. Early Stage VC | 27-Nov-2006 | $1.91M | $1.91M | Completed | Product Development | |
| 1. University Spin-Out | 01-Jan-2006 | Completed | Startup |
Myconostica Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| D Preference | ||||||||
| C Preference | ||||||||
| Ordinary | 250 | $0.015101 | $60.4 | $60.4 | 1x | $60.4 | 0% | |
| B Preference | 54,545 | $0.015101 | $27.69 | $27.69 | 1x | $27.69 | 0.53% |
Myconostica Patents
Myconostica Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-201005622-D0 | Assay for candida glabrata | Inactive | 01-Apr-2010 | ||
| WO-2011121288-A2 | Assays for candida glabrata | Inactive | 29-Mar-2010 | ||
| WO-2011121288-A3 | Assays for candida glabrata | Inactive | 29-Mar-2010 | ||
| GB-0918926-D0 | Assay | Inactive | 28-Oct-2009 | ||
| WO-2011030091-A1 | Assay for candida species | Inactive | 11-Sep-2009 | C12Q1/6816 |
Myconostica Signals
Myconostica Former Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Amphion Innovations | Venture Capital | Minority | ||
| IPSA( Asset Management) | Venture Capital | Minority | ||
| MTI Partners | Venture Capital | Minority | ||
| Medac Pharma | Corporation | Minority | ||
| Medicis Capital | Venture Capital | Minority |
Myconostica FAQs
-
When was Myconostica founded?
Myconostica was founded in 2006.
-
Where is Myconostica headquartered?
Myconostica is headquartered in Camberley, United Kingdom.
-
What is the size of Myconostica?
Myconostica has 13 total employees.
-
What industry is Myconostica in?
Myconostica’s primary industry is Diagnostic Equipment.
-
Is Myconostica a private or public company?
Myconostica is a Private company.
-
What is Myconostica’s current revenue?
The current revenue for Myconostica is .
-
How much funding has Myconostica raised over time?
Myconostica has raised $10.6M.
-
Who are Myconostica’s investors?
Amphion Innovations, IPSA( Asset Management), MTI Partners, Medac Pharma, and Medicis Capital are 5 of 6 investors who have invested in Myconostica.
-
When was Myconostica acquired?
Myconostica was acquired on 23-May-2011.
-
Who acquired Myconostica?
Myconostica was acquired by Cambridge Clinical Laboratories.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process